Interviews

Interviews

FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue

In the midst of the rising popularity of glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their compounded versions, the US Food…

Frankie Fattorini

Interviews

Podcast: The FDA’s emerging aversion to advisory committees

Interviews

Podcast: How oral GLP-1RAs are set to impact the obesity market

Interviews

Can oral GLP-1RAs deliver on the promise of accessible obesity care?

Interviews

VPAG stalemate threatens to exclude innovative medicines from the UK

Interviews

Uncertainty around tariffs is a disincentive for pharma onshoring in the US

Interviews

FDA genAI reviews hinge on clarity of dossiers

Interviews

Saving shelved ultra-rare therapies through unorthodox funding

Interviews

People-focused cancer care demands policy support

Interviews

PrEP therapies offer new hope in HIV preventive landscape as vaccine failures amass

Interviews

Will the tide turn for the wave of pharma layoffs?

Interviews

Clinical research in the UK must build on industry collaboration, says NIHR director

Interviews

How NVIDIA grew with the healthcare market instead of pushing into it

Features

Drug development costs predicted to soar as BIOSECURE Act gains momentum

Phalguni Deswal

Interviews

Boehringer Ingelheim plans sustainability work for the long term

Interviews

Q&A: Cell and gene therapy value assessments need a rework to allow access

Interviews

Q&A: BARDA wants to back tech that can combat multiple infections, says director

Phalguni Deswal

Interviews

Q&A: Increasing awareness around digital therapeutics key to realising full potential

Interviews

Q&A: Regulatory reform necessary to improve obesity drug access

Interviews

Bupa is leveraging its unique position to develop IoT and AI features

Interviews

Q&A: Exploring the challenges behind oncology trials

Interviews

Q&A: Tackling the rise of fake anti-obesity drugs on the market

Interviews

Q&A: European Pharmaceutical legislation: hindrance or help?

Interviews

Q&A: UK pharma manufacturing prepares for imminent shake up in 2024

Interviews

What does CSRD mean for the pharmaceutical industry? ENGIE Impact explains

Interviews

Q&A: How the Henrietta Lacks settlement challenges biotech’s view on ethics

Interviews

‘Migrant-led start-ups do better’: interview with the founder of One Way Ventures

Sebastian Shehadi

Interviews

Angola’s economic rebound and the impact of the ZEE free-trade zone

Sebastian Shehadi

Interviews

Q&A: How can the US maintain access to essential drugs?

Interviews

Q&A: How Big Pharma implements analytics in continuous manufacturing

Interviews

Q&A: As RSV vaccine approvals loom, regulators need to devise vaccination strategies

Interviews

‘Pejorative politics are the problem, not migrants’: CEO of Fladgate Partnership Adrian Bridge

Sebastian Shehadi

Interviews

Q&A: A decade on, what’s next for CAR-T therapies?

Interviews

Q&A: Cleaning up the antibiotic resistance problem in dentistry

Interviews

Biosimilar Q&A: Is an interchangeability designation still relevant?

Ukraine Crisis

Ukraine looks to a future as a hub for medical tourism

Sebastian Shehadi

Comment

Palestine Action: The sabotage experts turning heads across the business world

Sebastian Shehadi

Partner Content

Why moving from Europe to Charleston SC to work in medtech was a win-win for me and my family

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close